SLC5A2 and type 2 diabetes mellitus: This was implemented in a cohort study of adult patients with type 2 diabetes (T2D) initiating canagliflozin, the first marketed sodium glucose co‐transporter 2 (SGLT2) inhibitors in the United States, compared to two active comparators between March 2013 and September 2015.